Hepion Pharmaceuticals, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
OQB
Anson Funds Management LP and related entities reported a 4.9% beneficial ownership stake in Hepion Pharmaceuticals, Inc., including shares from warrants.
OQB
S.H.N. Financial Investments Ltd. has amended its Schedule 13G, reporting zero beneficial ownership in Hepion Pharmaceuticals, Inc.
OQB
Anson Funds Management LP and its affiliates have reported a 9.9% beneficial ownership stake in Hepion Pharmaceuticals, Inc., primarily for investment purposes.
OQB
S.H.N. Financial Investments Ltd. has reported a 9.99% beneficial ownership stake in Hepion Pharmaceuticals, Inc., including shares acquired through a recent offering.
OQB
SCHEDULE: Bigger Capital Fund Discloses 9.99% Stake in Hepion Pharmaceuticals Before Selling All Shares
Bigger Capital Fund, along with its general partner and managing member, reported a 9.99% beneficial ownership in Hepion Pharmaceuticals before selling all shares, excluding those issuable upon warrant exercise, by January 24, 2025.